All Pharma News
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Pulmonary Fibrosis

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Pulmonary Fibrosis
BUSINESSWIRE
14 Dec 2023
Share Share
Agomab Appoints Angelika Jahreis as Member of the Board of Directors

Agomab Appoints Angelika Jahreis as Member of the Board of Directors
BUSINESSWIRE
29 Nov 2023
Share Share
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
BUSINESSWIRE
11 Oct 2023
Share Share
Agomab uses $100M series C to push Crohn`s drug through phase 2

Agomab uses $100M series C to push Crohn`s drug through phase 2
James Waldron FIERCE BIOTECH
11 Oct 2023
Share Share
Agomab Receives FDA Fast Track Designation for AGMB-129

Agomab Receives FDA Fast Track Designation for AGMB-129
BUSINESSWIRE
05 Oct 2023
Share Share
Agomab Reports Positive Phase 1 Results with AGMB-129

Agomab Reports Positive Phase 1 Results with AGMB-129
BUSINESSWIRE
02 Feb 2023
Share Share
Agomab Raises Additional $40.5 Million Through Series B Extension

Agomab Raises Additional $40.5 Million Through Series B Extension
BUSINESSWIRE
13 Jul 2022
Share Share
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference

Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference
BUSINESSWIRE
12 Jan 2022
Share Share
Agomab Therapeutics Completes Acquisition of Origo Biopharma

Agomab Therapeutics Completes Acquisition of Origo Biopharma
BUSINESSWIRE
14 Dec 2021
Share Share
Agomab Therapeutics to Acquire Origo Biopharma

Agomab Therapeutics to Acquire Origo Biopharma
BUSINESSWIRE
28 Oct 2021
Share Share